

## Frost & Sullivan Recognizes Immunomic Therapeutics for its Pioneering DNA Vaccine Technology – LAMP or Lysosome-Associated Membrane Protein

**LANCASTER, PA — MAY 17, 2010** — Based on its recent analysis of the DNA vaccines market, Frost & Sullivan recognizes Immunomic Therapeutics, Inc. with the 2010 North American Frost & Sullivan Award for Technology Innovation for its next generation vaccine technology known as LAMP (Lysosome-Associated Membrane Protein).

DNA vaccines have been under development for several years and hold great promise to address key human health needs. They are simple to manufacture, easy to manipulate, and have enhanced stability. The market for DNA vaccines and vaccines as a category is expected to mushroom with several new products having been recently approved by the FDA (e.g., Gardasil® for HPV). The issue for many DNA vaccines to reach full regulatory approval has been the lack of sustainable systemic response due to inadequate T-helper cell involvement.

Immunomic Therapeutics' LAMP-vax technology induces a robust immune response following vaccination by directing the antigen into the MCH-II / helper T-cell pathway in dendritic cells. As a result, LAMP-vax vaccines cause both the humoral (i.e., antibody) and cellular pathways to activate resulting in the formation of antigen specific antibodies and cytotoxic T-lymphocytes (a.k.a killer T-cells). Thus, the full immune system is engaged to respond to the vaccine; the properties of LAMP technology are well-supported in numerous scientific publications and recently in human clinical studies.

“The uniqueness of the technology is that the antigen can be directly delivered into the lysosome and dendritic cell...[and consequently] the antigen [is] not be delivered into the patient as a free peptide or protein,” says Frost & Sullivan Research Analyst Nandini Ishwarakrishnan. “Also, since the company’s technology does not introduce any kind of free allergen but relies on the use of MHCII molecules [for immune presentation], this approach is both feasible and appealing for allergy immunotherapy.”

Among Immunomic Therapeutics active partnerships is a relationship with the Geron Corporation, who has applied the LAMP technology for use in cancer vaccines. Two promising clinical studies have shown the safety and efficacy of the vaccine. LAMP could also be incorporated into many vaccines currently under development to enhance efficacy.

“Research studies have shown that the technology may also be suitable to applications such as HIV and other infectious diseases,” notes Ishwarakrishnan. “Immunomic Therapeutics is also focused on the use LAMP vaccine in relatively newer applications such as food allergies.”

The company has patents on its core technology covering the global market. A new patent pending in the U.S., Japan and Europe (issued in Australia) extends the exclusive rights to the LAMP molecule for future vaccine initiatives and exciting new and innovative patent work is underway. The company has published regarding LAMP technology in renowned journals such as Gene Therapy, Vaccine, and Immunology to name a few. “Our strength lays in our people, says Bill Hearl, the company’s CEO, which includes our co-founder Dr. Tom August, a Distinguished Professor at the Johns Hopkins University”. Equipped with a strong management team, outstanding science, and continual innovation, the company is poised for success now and in the future.

For these achievements, Immunomic Therapeutics is the worthy recipient of the 2010 North American Frost & Sullivan Award for Technology Innovation in the DNA vaccines market.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

**About Immunomic Therapeutics, Inc.**

Immunomic Therapeutics, Inc. is a developmental stage biotechnology company based in Lancaster, PA with laboratories in Rockville, Maryland. The Company is developing next generation vaccines based on LAMP-vax Technology for application to allergy, cancer and infectious diseases. The company is headed by a strong and capable management team and scientific and business advisors who have several years of combined experience in the biotechnology industry. To learn more about the company, please visit our website at <http://www.immunomix.com>.

**About Frost & Sullivan**

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit <http://www.awards.frost.com>.

**Contact:**

Jake Wengroff  
210.247.3806

[jake.wengroff@frost.com](mailto:jake.wengroff@frost.com)